Applicability of EU(7)-PIM criteria in cross-national studies in European countries

[Abstract] Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015–November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drugregulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8–21.7% not marketed PIMs) and less than 20% of PIMs were available as over-thecounter medications (except in Turkey, 46.4–48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017–2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.European Commision; project INOMED CZ.02.1.01/0.0/0.0/18_069/001004

Application of explicite criteria of medications potentially inappropriate in the old age in the evaluation of quality of prescribing (III.)

Introduction: Propotion of older people is rapidly increasing in the world population. Elderly represents a specific, heterogenous population which is because of many reasons more vulnerable to some adverse drug events. Many explicit criteria of potentially inappropriate medication used in the elderly have been developed in order to improve the quality and safety of geriatric pharmacotherapy. These criteria represent basic tools, defining fundamental prescribing rules for the evaluation of appropriate choice and dosing of medications in the old age and for the evaluation of potentially inappropriate prescriptions in older patiens. The aim of the diploma thesis was to compare advantages and disadvantages of explicit criteria published until the end of 2015 year and to summarizea list of allpotentially inappropriate medications in the elderly (regardless of diagnoses and concomitantly used medications), applicable in the epidemiological studies of the EU COST Action 1402project and in subsequent studies. Methods: Using systematic literature search in PubMed dataset, conducted in the period 04/2015 - 12/2015, all explicit and explicit- implicit criteria (published in the foreign peer- reviewed scientific journals bythe end of year 2015 and validated by expert panels) have been identified. Information..

Applicability of EU(7)-PIM criteria in cross-national studies in European countries. Therapeutic Advances in Drugs Safety. 2019. https://doi.org/10.1177/2042098619854014

The EU project EUROAGEISM H2020 (2017–2021), ESR7 project, focuses on prescribing of high-risk medications in older adults (so called PIMs, potentially inappropriate medications) and regulatory measures related to these medications, particularly in European countries. The EU7-PIM (potentially inappropriate medication) criteria presents the most comprehensive and up-to-date list of high-risk medications in older adults utilized in research in Europe. However, several country-specific studies documented differences in approval rates of high-risk medications for geriatric patients and different regulatory measures across EU countries. This scientific article describes the differences between 6 European countries (Czech Republic, Spain, Portugal, Turkey, Hungary and Republic of Serbia) in approval rates and marketing of high-risk medications in older adults using the EU(7)-PIM criteria in comparison to the most known and most utilized American Geriatric Society (AGS) Beers 2015 PIM criteria.article in the foreign journal with the I